Nasdaq Welcomes Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM) to The Nasdaq Stock Market

NEW YORK, Dec. 18, 2014 -- Nasdaq (NDAQ) announced that trading of Bellicum Pharmaceuticals, Inc. (BLCM), a biopharmaceutical company, commenced on The Nasdaq Stock Market on December 18, 2014.

Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company is using its technology platform to engineer and control components of the immune system in real time.

Published: 18 December 2014
Written by Editor
Nasdaq   Up on News   New Listing  
Read more: Bellicum Pharmaceuticals Inc ( BLCM )

FDA Approves INTERCEPT Blood System for Plasma

Cerus’ Blood Safety Technology is Indicated to Reduce the Risk of Transfusion-Transmitted Infections from Plasma Components

CONCORD, Calif.-- Cerus Corporation (CERS) today announced that the U.S. Food and Drug Administration (FDA) has approved the INTERCEPT Blood System for plasma. The INTERCEPT plasma system is approved for ex vivo preparation of plasma in order to reduce the risk of transfusion-transmitted infection (TTI) when treating patients requiring therapeutic plasma transfusion.

The INTERCEPT Blood System inactivates a broad spectrum of enveloped viruses, non-enveloped viruses, Gram-positive and Gram-negative bacteria, spirochetes and parasites.

Published: 17 December 2014
Written by Editor
Nasdaq   FDA HC Decision   Up on News  
Read more: Cerus Corporation ( CERS )

Auspex Announces Positive Topline Results From Registration Trial of SD-809 for Chorea Associated With Huntington's Disease

Pivotal Phase 3 Trial Met Primary and Multiple Key Secondary Efficacy Endpoints; Favorable Safety and Tolerability Demonstrated
ARC-HD Trial Shows Successful Maintenance of Chorea Control After Switch to SD-809
NDA Submission Planned by Mid-2015
Conference Call Scheduled for 4:30 PM ET / 1:30 PM PT Today

LA JOLLA, Calif., Dec. 16, 2014 -- Auspex Pharmaceuticals, Inc. (ASPX), a biopharmaceutical company dedicated to developing innovative medicines for people with movement disorders and other rare diseases, today announced positive topline efficacy and safety results from its Phase 3 registration trial evaluating SD-809 for the treatment of chorea associated with Huntington's disease (HD), called First-HD.

Published: 17 December 2014
Written by Editor
Nasdaq   Up on News   Project Update  
Read more: Auspex Pharmaceuticals Inc ( ASPX )

Novogen Announces Breakthrough Discovery in the Treatment of Melanoma

SYDNEY, Dec. 16, 2014  -- Novogen Limited (ASX:NRT; NASDAQ:NVGN), Australian/US biotechnology company, today announces that it has confirmed that its lead candidate product, TRXE-009, originally developed for the treatment of brain cancers, has been shown in pre-clinical studies also to be highly active against melanoma.

The Company believes this is an important breakthrough discovery for two reasons. The first is that it confirms that TRXE-009 is an important new potential treatment for melanoma, including for the treatment of secondary brain cancers due to melanoma, for which there currently are no effective therapies. The second is that it offers evidence for the first time of an hypothesized link between brain cancer and melanoma.

Published: 16 December 2014
Written by Editor
Nasdaq   Project Update  
Read more: Novogen Limited ( NVGN )

Advaxis Announces FDA Acceptance of Its Investigational New Drug Application to Commence Clinical Trials of ADXS-HPV in Combination With MedImmune's MEDI4736 for the Treatment of HPV-Associated Cancers

Companies Plan to Immediately Initiate Phase 1/2 Clinical Trial in Cervical and Head & Neck Cancer

PRINCETON, N.J., Dec. 15, 2014  -- Advaxis, Inc. (ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to conduct a Phase 1/2 clinical study of ADXS-HPV (ADXS11-001) alone or in combination with MedImmune's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, for the treatment of advanced, recurrent or refractory human papillomavirus (HPV)-associated cervical cancer and HPV-associated head and neck cancer. The trial is expected to begin patient enrollment in early 2015.

Published: 15 December 2014
Written by Editor
Nasdaq   FDA HC Decision   Up on News  
Read more: Advaxis Inc ( ADXS )
  1. Sorrento Therapeutics Inc ( SRNE )
  2. MEI Pharma Inc ( MEIP )
  3. ChemoCentryx Inc ( CCXI )
  4. Calithera Biosciences Inc ( CALA )
  5. Immunovaccine Inc ( IMV )